Zacks: Brokerages Expect Motus GI Holdings, Inc. (NASDAQ:MOTS) Will Post Quarterly Sales of $240,000.00

Brokerages predict that Motus GI Holdings, Inc. (NASDAQ:MOTSGet Rating) will post $240,000.00 in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Motus GI’s earnings, with the lowest sales estimate coming in at $100,000.00 and the highest estimate coming in at $400,000.00. Motus GI posted sales of $100,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 140%. The firm is expected to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Motus GI will report full year sales of $1.29 million for the current financial year, with estimates ranging from $610,000.00 to $1.90 million. For the next year, analysts anticipate that the company will report sales of $6.39 million, with estimates ranging from $2.98 million to $9.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Motus GI.

Motus GI (NASDAQ:MOTSGet Rating) last released its earnings results on Tuesday, March 29th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). Motus GI had a negative net margin of 5,331.94% and a negative return on equity of 152.78%. The firm had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.14 million. During the same period last year, the business earned ($0.12) earnings per share.

MOTS has been the subject of several recent research reports. Alliance Global Partners lowered their target price on shares of Motus GI from $1.75 to $1.40 in a report on Wednesday, January 26th. HC Wainwright lowered their target price on shares of Motus GI from $2.00 to $1.50 and set a “na” rating for the company in a report on Monday. Finally, Colliers Securities reiterated a “buy” rating on shares of Motus GI in a report on Tuesday, March 22nd.

A number of hedge funds and other institutional investors have recently made changes to their positions in MOTS. Morgan Stanley grew its position in Motus GI by 41.7% in the 2nd quarter. Morgan Stanley now owns 51,000 shares of the company’s stock worth $53,000 after purchasing an additional 15,000 shares during the period. Citadel Advisors LLC grew its position in Motus GI by 276.3% in the 2nd quarter. Citadel Advisors LLC now owns 46,447 shares of the company’s stock worth $48,000 after purchasing an additional 34,103 shares during the period. BlackRock Inc. grew its position in Motus GI by 13.5% in the 3rd quarter. BlackRock Inc. now owns 202,808 shares of the company’s stock worth $139,000 after purchasing an additional 24,100 shares during the period. Millennium Management LLC grew its position in Motus GI by 20.4% in the 3rd quarter. Millennium Management LLC now owns 118,652 shares of the company’s stock worth $82,000 after purchasing an additional 20,110 shares during the period. Finally, LPL Financial LLC bought a new stake in Motus GI in the 4th quarter worth approximately $25,000. Institutional investors own 7.48% of the company’s stock.

Shares of MOTS stock traded up $0.02 during trading hours on Tuesday, hitting $0.26. 144,717 shares of the company’s stock traded hands, compared to its average volume of 1,141,885. The stock’s fifty day simple moving average is $0.31 and its two-hundred day simple moving average is $0.42. Motus GI has a 12-month low of $0.23 and a 12-month high of $1.22. The stock has a market cap of $14.05 million, a price-to-earnings ratio of -0.66 and a beta of 2.40. The company has a quick ratio of 6.42, a current ratio of 6.63 and a debt-to-equity ratio of 1.20.

Motus GI Company Profile (Get Rating)

Motus GI Holdings, Inc, a medical technology company, develops Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.

Featured Stories

Get a free copy of the Zacks research report on Motus GI (MOTS)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Motus GI (NASDAQ:MOTS)

Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with's FREE daily email newsletter.